Multidisciplinary approach of a locally advanced adult alveolar rhabdomyosarcoma of paranasal sinuses: a case report and literature review*

Maider Campo1, Sonia Flamarique1, Gemma Asin1, Ignacio Vílus1, Alejandra Lacalle2, Fernando Mañeru2, Coro Zubimendi4, Miguel A. Resano5, Javier Saenz6, Fernando Arias1

1 Radiation Oncology Department, Complejo Hospitalario de Pamplona Pamplona, Spain
2 Medical Oncology Department, Complejo Hospitalario de Pamplona Pamplona, Spain
3 Physics Department, Complejo Hospitalario de Pamplona Pamplona, Spain
4 Otorhinolaryngology Department, Complejo Hospitalario de Pamplona Pamplona, Spain
5 Pathology Department, Complejo Hospitalario de Pamplona Pamplona, Spain
6 Radiology Department, Complejo Hospitalario de Pamplona Pamplona, Spain

Rhinology Online, Vol 1: 104 - 107, 2018
http://doi.org/10.4193/RHINOL/18.034

*Received for publication: July 18, 2018
Accepted: September 11, 2018

Abstract
Alveolar rhabdomyosarcoma (ARMS) is a rare soft-tissue malignancy constituting less than 1% of soft-tissue sarcomas. In this article we are describing a rare case of ARMS arising in the paranasal sinuses of an adult patient. We emphasize the multidisciplinary treatment administered, thanks to which the patient remains alive and free of disease for six years after the initial diagnosis.

Key words: paranasal sinuses, paranasal neoplasms, ethmoidal sinus

Introduction
Alveolar rhabdomyosarcoma (ARMS) is a rare soft-tissue malignancy constituting less than 1% of soft-tissue sarcomas11. About 25% of those occur in the head and neck, where typical sites include orbit, soft tissues of the cheek and paranasal sinuses21. It primarily affects children and adolescents however it also occasionally occurs in adults.

We describe a rare case of ARMS arising in the paranasal sinuses of an adult patient.

Case report
A 65-year-old woman was presented to our hospital with a year-long history of oppressive headaches. Her past history was otherwise unremarkable.

Computed tomography (CT) revealed a mass in the ethmoidal air cells and left sphenoidal sinus. The nasal endoscopic examination carried out by our Ear Nose and Throat (ENT) Department showed a mass located in the roof of left nasal fossa. Head and neck physical examination revealed evidence of a palpable, non-mobile, latero-cervical lymph node on the left side.

Subsequent T2-weighted magnetic resonance imaging (MRI) showed an aggressive mass in the left ethmoidal sinus (Figure 1). In addition, there were retropharyngeal and upper jugular lymphadenopathies. PET-CT ruled-out distance metastasis. Fine-needle aspiration showed an undifferentiated carcinoma. Microscopic examination of the biopsy specimen revealed a rounded-cell solid tumour, which had grown into solid nest and cords separated by fibrous septa, defining an alveolar pattern. To confirm the diagnosis, FISH analysis was then performed to evaluate for that FKHR gene (13q14) break (Figure 2).

The multidisciplinary tumour board decided to administer 3 cycles of induction chemotherapy, consisting of ifosfamide, doxorubicine and vincristine, resulting in a major response (Figure 3). After that, the patient gave consent for excision of the ethmoidal mass and ipsilateral functional neck dissection. On final pathology analysis, two section margins were reported to contain a residual tumour. To reduce the risk of locoregional recurrence, the patient received adjuvant radiotherapy 60Gy in 30 fractions of 2Gy, using IMRT (Figure 4).

The patient had been recurrence-free for 3 years when in a flexible fibreoptic nasal test we observed a left side protrusion in the nose. MRI showed local tumour recurrence in the left maxillary sinus (Figure 5). An extensive metastatic work-up was negative. With a diagnosis of recurrence ARMS, the patient received a second course of chemotherapy (ifosfamide, vincrsitine, Adriamycin, MESNA) resulting in a partial response. The patient was...
A case of adult alveolar rhabdomyosarcoma of paranasal sinuses

again operated on tumour recurrence. The histological analysis showed the section margin to be positive in maxillary sinus, administrating 60gy at 2 Gy per fraction over the tumour bed. The patient tolerated the treatment well and now is alive, with a disease-free survival of 33 months after the completion of the second treatment.

Discussion
Rhabdomyosarcoma (RMS) is a high-grade neoplasm of mesenchymal originates from the primitive skeletal muscle cells. It is the most common soft tissue sarcoma in childhood and adolescence, but it is extremely rare in adults.

Alveolar RMS is an aggressive subtype with a distinct histology, containing small and rounded cells. Typically, ARMS is rare in the head and neck, and occurs in the deep soft tissues of the lower extremities. Their natural clinical course is indolent and slow usually, presenting functional impairment or as a slowly enlarging mass, as seen in our case. Haematogenous spread is the typical route of metastasis, the lung being the most common site in 40-60% of cases. However, lymphatic metastases are also seen in around 7-10% of cases.

The diagnosis of ARMS is based on the combination of imaging with very elaborated analyses of the histology, immunochemical and molecular profile. Microscopically, ARMS is characterized by small and rounded cells, containing an abundant clear cytoplasm, with fibrovascular septae separating the tumor cells into nests.

Genetic alterations play an important role in the pathogenesis of the rhabdomyosarcoma. The World Health Organization (WHO) recently revised the classification of RMS subtypes as alveolar rhabdomyosarcoma (ARMS), embryonal rhabdomyosarcoma (ERMS), pleomorphic rhabdomyosarcoma (PRMS), and sclerosing/spindle cell rhabdomyosarcoma (SRMS) in 2013. The two major histological subtypes of RMS are alveolar RMS, driven by the fusion protein PAX3-FKHR or PAX7-FKHR, and embryonic RMS, which is usually genetically heterogeneous.

Effectively, ARMS have a characteristic translocation t(2;13), fusing the PAX3 gene (regulate transcription during neuro-muscular development) with the FKHR gene (a member of the family of transcription factors). It is hypothesized that this fusion transcription factor inappropriately activates transcription of the genes that contribute to a transformed phenotype. In the same way, the rupture of the FKHR gene has been associated to this histology, as seen in our case.

Because of their extreme rarity, inclusion of the ARMS subtype in the differential diagnosis of small round cell tumors of the head and neck region in patients over the age of 45 years is often neglected.

Due to the rarity of ARMS of the head and neck, having only
isolated case reports, the optimal treatment plan has not been clearly elucidated. Multimodality treatment protocols, including surgery, radiotherapy and chemotherapy, have improved the outcome over recent decades\(^6\). Local control is the main objective in the treatment of head and neck RMS. Like most soft tissues sarcomas, the main treatment of primary ARMS is complete surgical removal using a wide-local excision. The goal of obtaining negative margins after surgical resection has been shown to increase local control and survival rates. Typically, neck dissection is only utilized when palpable nodes are present, rather than prophylactically. Depending on the tumor location, disease extension and the Center experience, endoscopic surgery can be used\(^6\).

Radiation therapy plays an important role in the treatment of ARMS\(^6\). It is used to control local microscopic or gross residual disease in such instances, in cases where head and neck localization tumours often cannot be completely removed with surgery. Early guidelines recommended dosage as high as 55 to 60 Gy for control of the primary tumour. General radiation therapy guidelines have evolved with sequential intergroup studies, concluding that for residual microscopic disease 40-45 Gy appears to be sufficient to achieve local control and 45-50 Gy for gross residual disease.

The development of adjuvant and neoadjuvant chemotherapy has increased survival rates in patients with localized disease to approximately 60%. Combination agents for known activity in the rhabdomyosarcoma include ifosfamide, vincristine, doxorubicine and cyclophosphamide\(^{10,11}\). The initial approach of our multidisciplinary tumour board was neoadjuvant chemotherapy, due to the unresectability of initial tumour, following surgical excision of the mass and ipsilateral neck dissection. The section margins were affected, so adjuvant radiotherapy was included in the treatment.

Despite treatment improvements, the long-term prognosis for ARMS has remained poor due to the high rate of metastatic disease, being 71% at five years for patients presenting with localized disease, dropping to 20% for patients presenting with metastases. The local recurrence rate has been similar, ranging from 10-25%. In our case, our patient obtained 3-years disease-free with the initial therapy and the same treatments were included in the recurrence, obtaining major response again. Now after 5 years, the patient is alive with no local or distance disease.

The rarity of ARMS in the head and neck region and the smaller clinical series make it difficult to determine prognostic factors for survival.

**Conclusion**

In conclusion, our study reports a rare case of ARMS in an infrequent location. Due to the uncommon nature of the disease, diagnosis can be difficult, and analyses of the histopathology and molecular profile features are necessary for confirmation. The optimal treatment for ARMS has not yet been clearly elucidated. A multidisciplinary approach to these patients with surgery, radiotherapy and chemotherapy is the best current therapy, though long-term survivals remains poor.

**Authorship contribution**

All the authors have contributed to the draft of the article and accepted the final version.

**Conflict of interest**

No known conflict of interest.

---

**References**


A case of adult alveolar rhabdomyosarcoma of paranasal sinuses


F. Arias
Department of Radiation Oncology
Complejo Hospitalario de Navarra
Pamplona
Spain

Tel: 0034848422162.
E-mail: fariasde@cfnavarra.es
farias.delavega@outlook.es